TRAF6 is over-expressed in pancreatic cancer and promotes the tumorigenicity of pancreatic cancer cells
暂无分享,去创建一个
Wenchuan Wu | D. Jin | W. Lou | Xiaoling Ni | Y. Rong | Dansong Wang | T. Kuang | Lei Zhang
[1] C. Croce,et al. Pluripotent stem cell miRNAs and metastasis in invasive breast cancer. , 2014, Journal of the National Cancer Institute.
[2] Xiaohong Xu,et al. Neutralizing murine TGFβR2 promotes a differentiated tumor cell phenotype and inhibits pancreatic cancer metastasis. , 2014, Cancer research.
[3] Heng Zhao,et al. TRAF6 promoted the tumorigenicity of esophageal squamous cell carcinoma , 2013, Tumor Biology.
[4] B. Koller,et al. The innate immune sensor NLRC3 attenuates Toll-like receptor signaling via modification of the signaling adaptor TRAF6 and transcription factor NF-κB , 2012, Nature Immunology.
[5] S. Lam,et al. TRAF6 is an amplified oncogene bridging the RAS and NF-κB pathways in human lung cancer. , 2011, The Journal of clinical investigation.
[6] G. Krissansen,et al. Downregulation of nuclear factor-kappaB p65 subunit by small interfering RNA synergizes with gemcitabine to inhibit the growth of pancreatic cancer. , 2010, Cancer letters.
[7] Peter Olson,et al. Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner. , 2010, Cancer cell.
[8] A. Sood,et al. Nuclear Factor-κB p65/relA Silencing Induces Apoptosis and Increases Gemcitabine Effectiveness in a Subset of Pancreatic Cancer Cells , 2008, Clinical Cancer Research.
[9] C. Heldin,et al. The type I TGF-β receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner , 2008, Nature Cell Biology.
[10] R. Berardi,et al. COX-2 and NF-KB Overexpression Is Common in Pancreatic Cancer but Does Not Predict for COX-2 Inhibitors Activity in Combination With Gemcitabine and Oxaliplatin , 2007, American journal of clinical oncology.
[11] W. Weichert,et al. High expression of RelA/p65 is associated with activation of nuclear factor-κB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis , 2007, British Journal of Cancer.
[12] N. Chandler,et al. Increased expression of NF-κB subunits in human pancreatic cancer cells1,2 ☆ , 2004 .
[13] R. Cardiff,et al. Mammary tumor latency is increased in mice lacking the inducible nitric oxide synthase , 2003, International journal of cancer.
[14] A. Arlt,et al. Role of NF-κB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death , 2003, Oncogene.
[15] B. Evers,et al. Inflammation and the development of pancreatic cancer. , 2002, Surgical oncology.
[16] David Baltimore,et al. Inducibility of κ immunoglobulin enhancer-binding protein NF-κB by a posttranslational mechanism , 1986, Cell.
[17] E. Giovannetti,et al. Role of CYB5A in pancreatic cancer prognosis and autophagy modulation. , 2014, Journal of the National Cancer Institute.
[18] G. La Torre,et al. A Systematic Review of Resectability and Survival After Concurrent Chemoradiation in Primarily Unresectable Pancreatic Cancer , 2009, Annals of Surgical Oncology.
[19] Douglas B. Evans,et al. Function of nuclear factor kappaB in pancreatic cancer metastasis. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[20] Douglas B. Evans,et al. Function of Nuclear Factor κB in Pancreatic Cancer Metastasis , 2003 .
[21] Douglas B. Evans,et al. The Nuclear Factor-κB RelA Transcription Factor Is Constitutively Activated in Human Pancreatic Adenocarcinoma Cells , 1999 .
[22] A. Baldwin,et al. The NF-kappa B and I kappa B proteins: new discoveries and insights. , 1996, Annual review of immunology.
[23] A. Baldwin,et al. THE NF-κB AND IκB PROTEINS: New Discoveries and Insights , 1996 .
[24] D. Baltimore,et al. Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. , 1986, Cell.